Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.
Yu PY, et al. Among authors: guttridge dc.
PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.
PLoS One. 2017.
PMID: 28750090
Free PMC article.